Literature DB >> 20164537

ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.

Alessandra Trojani1, Marco Montillo, Michele Nichelatti, Alessandra Tedeschi, Chiara Colombo, Silvio Veronese, Maria Angela Mura, Francesca Ricci, Barbara Scarpati, Anna Colosimo, Milena Lodola, Enrica Morra.   

Abstract

BACKGROUND: New prognostic factors such as IgVh mutational status, ZAP-70 protein expression and cytogenetic abnormalities have shown to offer important prognostic information for patients with chronic lymphocytic leukemia (CLL). Our aim was to evaluate the optimal cut-off for IgVh mutational status, ZAP-70 expression and cytogenetic abnormalities in association with disease progression defined as the need for treatment within 3~years from diagnosis in 170 patients with B-CLL. DESIGN AND METHODS: Receiver operating characteristics (ROC) analysis and multivariate general linear models (GLMs) were used to investigate the most significant cut-off values of these biomarkers and their prognostic impact.
RESULTS: Our findings estimated that the optimal cut-off for IgVh mutation status and for ZAP-70 protein expression was 97% and 16.5% respectively and a high concordance between the two was demonstrated. We identified 30% as being the best-cut-off for 17p-, 11q- and 6q-. In univariate analysis 17p- was found to be a significant predictor of the event only for the whole population. Multivariate analysis including all biological parameters, identified 11q deletion as the only significant regressor.
CONCLUSIONS: We assessed that IgVh mutational status, ZAP-70 protein and 6q- are powerful prognostic markers. Analyses of all these factors revealed that 11q deletion was the strongest predictor of disease progression in B-CLL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164537     DOI: 10.3233/CBM-2009-0114

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  4 in total

1.  The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.

Authors:  Douglas E Gladstone; Amanda Blackford; Eunpi Cho; Lode Swinnen; Yvette Kasamon; Christopher D Gocke; Constance A Griffin; Javier Bolaños-Meade; Richard J Jones
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-01-28

Review 2.  The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.

Authors:  Cheng Wang; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

3.  Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.

Authors:  Douglas E Gladstone; Lode Swinnen; Yvette Kasamon; Amanda Blackford; Christopher D Gocke; Constance A Griffin; Javier Bolanos Meade; Richard J Jones
Journal:  Leuk Lymphoma       Date:  2011-08-18

4.  Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.

Authors:  Jose D Sandoval-Sus; Julio C Chavez; Samir Dalia; Syeda Mahrukh Hussnain Naqvi; Chetasi Talati; Lisa Nodzon; Mohamed A Kharfan-Dabaja; Javier Pinilla-Ibarz
Journal:  Leuk Lymphoma       Date:  2017-06-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.